Literature DB >> 16779557

O-[18F]fluoromethyl-L-tyrosine is a potential tracer for monitoring tumour response to chemotherapy using PET: an initial comparative in vivo study with deoxyglucose and thymidine.

Gengo Yamaura1, Takashi Yoshioka, Hiroshi Fukuda, Keichiro Yamaguchi, Manami Suzuki, Shozo Furumoto, Ren Iwata, Chikashi Ishioka.   

Abstract

PURPOSE: To compare the utility of a new artificial amino acid, O-[18F]fluoromethyl-L-tyrosine ([18F]FMT), for monitoring cancer chemotherapy with deoxyglucose and thymidine.
METHODS: [18F]FMT, [14C]deoxyglucose ([14C]DG) and [6-3H]thymidine ([3H]Thd) were applied in this study. A 2.5 mg/kg dose of mitomycin (MMC) was administered to AH272 rat hepatoma-bearing Donryu rats. Tumour uptake of each tracer was measured just before (baseline) and on days 1, 3, 5 and 7 after the MMC administration, 1 h after a mixture of [18F]FMT, [14C]DG and [3H]Thd had been injected, and was shown as DURs (% injected dose/gram tissue normalised for the rat body weight). Dual-tracer macroautoradiographs with [18F]FMT and [14C]DG were also prepared.
RESULTS: The tumour uptake for each tracer decreased earlier than did the tumour size. DURs (mean+/-SD) at baseline and on days 1, 3, 5 and 7 were as follows: [18F]FMT: 4.68+/-0.72, 3.34+/-0.66, 3.13+/-0.72, 3.42+/-0.45, 3.01+/-0.32; [14C]DG: 3.26+/-0.40, 3.09+/-0.55, 3.01+/-0.97, 2.28+/-0.35, 1.70+/-0.72; and [3H]Thd: 2.23+/-0.46, 1.54+/-0.45, 1.28+/-0.37, 1.35+/-0.20, 0.94+/-0.12. Decrease in [18F]FMT uptake compared with baseline was significant from day 1 (p<0.01), and the decrease in [3H]Thd uptake was also significant on day 1 (p<0.05) and days 3-7 (p<0.01). However, decrease in [14C]DG uptake was only significant from day 5 (p<0.01). Macroautoradiography suggested that the influence of inflammatory cells on the accumulation of [18F]FMT in tumours is smaller than that on the accumulation of [14C]DG.
CONCLUSION: [18F]FMT uptake shows a rapid and sensitive response to chemotherapy, comparable to that of [3H]Thd, suggesting that it may be applied as a powerful tracer for monitoring of proliferative activity after cancer chemotherapy using PET.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16779557     DOI: 10.1007/s00259-006-0126-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  33 in total

1.  Apoptosis and changes in glucose transport early after treatment of Morris hepatoma with gemcitabine.

Authors:  U Haberkorn; M E Bellemann; G Brix; H Kamencic; I Morr; U Traut; A Altmann; J Doll; J Blatter; R Kinscherf
Journal:  Eur J Nucl Med       Date:  2001-04

2.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

Review 3.  Fluorinated amino acids for tumour imaging with positron emission tomography.

Authors:  Peter Laverman; Otto C Boerman; Frans H M Corstens; Wim J G Oyen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-01-11       Impact factor: 9.236

Review 4.  18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma.

Authors:  Lale Kostakoglu; Stanley J Goldsmith
Journal:  J Nucl Med       Date:  2003-02       Impact factor: 10.057

5.  [18F]fluoromethyl triflate, a novel and reactive [18F]fluoromethylating agent: preparation and application to the on-column preparation of [18F]fluorocholine.

Authors:  Ren Iwata; Claudio Pascali; Anna Bogni; Shozo Furumoto; Kazunori Terasaki; Kazuhiko Yanai
Journal:  Appl Radiat Isot       Date:  2002-09       Impact factor: 1.513

6.  Active and passive mechanisms of [fluorine-18] fluorodeoxyglucose uptake by proliferating and prenecrotic cancer cells in vivo: a microautoradiographic study.

Authors:  R Kubota; K Kubota; S Yamada; M Tada; T Ido; N Tamahashi
Journal:  J Nucl Med       Date:  1994-06       Impact factor: 10.057

Review 7.  PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus.

Authors:  Lale Kostakoglu; Stanley J Goldsmith
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057

8.  Synthesis of L- and D-[methyl-11C]methionine.

Authors:  B Långström; G Antoni; P Gullberg; C Halldin; P Malmborg; K Någren; A Rimland; H Svärd
Journal:  J Nucl Med       Date:  1987-06       Impact factor: 10.057

9.  Carbon-11-methionine PET imaging of malignant melanoma.

Authors:  P Lindholm; S Leskinen; K Någren; P Lehikoinen; U Ruotsalainen; M Teräs; H Joensuu
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057

10.  Tracer feasibility for monitoring tumor radiotherapy: a quadruple tracer study with fluorine-18-fluorodeoxyglucose or fluorine-18-fluorodeoxyuridine, L-[methyl-14C]methionine, [6-3H]thymidine, and gallium-67.

Authors:  K Kubota; K Ishiwata; R Kubota; S Yamada; M Tada; T Sato; T Ido
Journal:  J Nucl Med       Date:  1991-11       Impact factor: 10.057

View more
  2 in total

Review 1.  Alternative PET tracers in head and neck cancer. A review.

Authors:  Jan Wedman; Jan Pruim; Jan L N Roodenburg; Gyorgy B Halmos; Johannes A Langedijk; Rudi A J O Dierckx; Bernard F A M van der Laan
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-12-27       Impact factor: 2.503

2.  Synthesis and evaluation of amino acid-based radiotracer 99mTc-N4-AMT for breast cancer imaging.

Authors:  Fan-Lin Kong; Mohammad S Ali; Yinhan Zhang; Chang-Sok Oh; Dong-Fang Yu; Mithu Chanda; David J Yang
Journal:  J Biomed Biotechnol       Date:  2011-04-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.